Hims & Hers Health Analyst Ratings
Jefferies Maintains Hold on Hims & Hers Health, Raises Price Target to $23
Hims & Hers Health Analyst Ratings
Hims & Hers Health Analyst Ratings
Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $24
After a 20% increase, there is room for growth, and XiaoCiti downgraded Hims & Hers Health (HIMS.US) to “neutral”
Hims & Hers Health Analyst Ratings
Citigroup Downgrades Hims & Hers Health to Neutral From Buy With $20 Price Target
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Hims & Hers Health's Strategic Growth in Weight Loss Market Warrants Buy Rating Despite Regulatory Risks
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Inotiv (NOTV) and Hims & Hers Health (HIMS)
Deutsche Bank Adjusts Hims & Hers Health Price Target to $16 From $14, Maintains Hold Rating
Buy Rating Affirmed for Hims & Hers Health Amidst Strong Quarterly Performance and Positive Outlook
Hims & Hers Health Analyst Ratings
Piper Sandler Maintains Neutral on Hims & Hers Health, Raises Price Target to $13
Jefferies Investment Bank: Downgraded the Hims & Hers Health (HIMS.US) rating from buy to hold, and the target price was adjusted from $17.00 to $15.00.
Hims & Hers Health Analyst Ratings
Hims & Hers Health (HIMS.US) was first covered by the Canadian Investment Banking Group, giving it a buying rating, with a target price of $20.00.
Hims & Hers Health Analyst Ratings
Hims & Hers Health Outperforms: Strong Sales Growth and Brand Value Reinforce Buy Rating